Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
NovoSeven 1mg (50,000units) inj vials
0211000Z0BBADAD
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 240,000unit inj vials
0211000Z0BBACAC
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 2mg (100,000units) inj pfs
0211000Z0BBAIAI
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 2mg (100,000units) inj vials
0211000Z0BBAEAE
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 5mg (250,000units) inj pfs
0211000Z0BBAJAJ
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 5mg (250,000units) inj vials
0211000Z0BBAFAF
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 60,000unit inj vials
0211000Z0BBAAAA
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 8mg (400,000units) inj pfs
0211000Z0BBAKAK
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoSeven 8mg (400,000units) inj vials
0211000Z0BBAGAG
|
NovoSeven | Factor VIIa (Recombinant) | Cardiovascular System | No data available |
|
NovoThirteen 2,500unit inj vials
0211000ABBBABAA
|
NovoThirteen | Factor XIII (Recombinant) | Cardiovascular System | No data available |
|
NovoThirteen 2,500unit inj vials (Imported (Denmark))
0211000ABBBAAAA
|
NovoThirteen | Factor XIII (Recombinant) | Cardiovascular System | No data available |
|
Octanate LV 1,000unit inj vials
0211000I0BSACBG
|
Octanate LV | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octanate LV 500unit inj vials
0211000I0BSADBF
|
Octanate LV | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 1,000unit inj vials
0211000I0AAAHAH
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 1,500unit inf vials
0211000I0AAALAL
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 2,000unit inj vials
0211000I0AAAIAI
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 250unit inj vials
0211000I0AAAFAF
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 3,000unit inf vials
0211000I0AAAPAP
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 500unit inj vials
0211000I0AAAGAG
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Odrik 1mg capsules
0205051U0BCABAB
|
Odrik | Trandolapril | Cardiovascular System | No data available |
|
Odrik 2mg capsules
0205051U0BCACAC
|
Odrik | Trandolapril | Cardiovascular System | No data available |
|
Odrik 500microgram capsules
0205051U0BCAAAA
|
Odrik | Trandolapril | Cardiovascular System | No data available |
|
Ofcram PR 200mg capsules
0209000L0BHAAAM
|
Ofcram PR | Dipyridamole | Cardiovascular System | No data available |
|
Omega 3 1000mg capsules
0212000ABBGAAAA
|
Omega 3 | Omega-3-acid ethyl esters | Cardiovascular System | No data available |
|
Opsumit 10mg tablets
0205010AABBAAAA
|
Opsumit | Macitentan | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.